Pre-made Ocrelizumab benchmark antibody ( Whole mAb, anti-MS4A1/CD20 therapeutic antibody, Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Ocrelizumab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ocrelizumab, sold under the brand name Ocrevus, is a pharmaceutical drug for the treatment of multiple sclerosis (MS). It is a humanized anti-CD20 monoclonal antibody.[3] It targets CD20 marker on B lymphocytes and hence is an immunosuppressive drug.[4] Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds.[4]
| Products Name (INN Index) | Pre-Made Ocrelizumab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody |
|---|---|
| INN Name | Ocrelizumab |
| Target | MS4A1 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | NFD |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | 4k7p:YX |
| Year Proposed | 2005 |
| Year Recommended | 2006 |
| Companies | Biogen,Biogen Idec,Chugai Pharmaceutical,Genentech,Roche |
| Conditions Approved | Multiple sclerosis |
| Conditions Active | NA |
| Conditions Discontinued | Eye disorders,Haematological malignancies,Lupus nephritis,Rheumatoid arthritis,Systemic lupus erythematosus |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | MS4A1 |
| Package |
